March 19, 2024•Press Release
A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis. Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries. The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective.
As head of chemistry, manufacturing & controls at the Bill & Melinda Gates Medical Research Institute, Piper Trelstad, Ph.D., and her team develop robust, innovative, and cost-effective manufacturing processes and ensure clinical supply availability for Gates MRI’s drug and vaccine candidates. Piper brings over 20 years of experience in vaccine…
February 15, 2023•Press Release, Written by Gates MRI
Calibr, a division of Scripps Research dedicated to the “bench to bedside” development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment.
November 16, 2023•Publication
As head of translational discovery at the Bill & Melinda Gates Medical Research Institute, Jared A. Silverman, Ph.D., drives products from idea to commercialization in disease areas that disproportionately impact vulnerable populations worldwide. Jared has more than 20 years of experience in drug discovery spanning multiple therapeutic areas, with a…
October 18, 2022•Press Release, Written by Gates MRI
Merck and the Bill & Melinda Gates Medical Research Institute today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB).
